Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/12/989   
Active ingredient: 2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
Indication: Treatment of ovarian cancer
Sponsor: AstraZeneca UK Limited
Charter Way, Macclesfield, Cheshire East SK10 2NA, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/04/2012 Orphan designation EMA/OD/151/11 (2012)2985 of 26/04/2012
19/05/2015 Transfer of orphan designation EMA/OD/151/11/T/01 (2015)3438 of 13/05/2015
22/02/2016 Change of name and/or address of sponsor